Fonteh P, Elkhadir A, Omondi B, Guzei I, Darkwa J, Meyer D
Department of Biochemistry, University of Pretoria, Pretoria, 0002, South Africa.
Biometals. 2015 Aug;28(4):653-67. doi: 10.1007/s10534-015-9851-y. Epub 2015 Apr 1.
Label free impedance technology enables the monitoring of cell response patterns post treatment with drugs or other chemicals. Using this technology, a correlation between the lipophilicity of metal complexes and the degree of cytotoxicity was observed. Au(L1)Cl (1), AuPd(L1)(SC4H8)Cl3 (1a) and Au(L2)Cl (2) [L1 = diphenylphosphino-2-pyridine; L2 = 2-(2-(diphenylphosphino)ethyl)-pyridine] were synthesised, in silico drug-likeness and structure-activity relationship monitored using impedance technology. Dose dependent changes in cytotoxicity were observed for the metal complexes resulting in IC50s of 12.5 ± 2.5, 18.3 ± 8.3 and 16.9 ± 0.5 µM for 1, 1a and 2 respectively in an endpoint assay. When a real time impedance assay was used, dose-dependent responses depicting patterns that suggested slower uptake (at a toxic 20 µM) and faster recovery of the cells (at the less toxic 10 µM) of the bimetallic complex (1a) compared to the monometallic complexes (1 and 2) was observed. These data agreed with the ADMET findings of lower aqueous solubility of 1a and non-ideal lipophilicity (AlogP98 of 6.55) over more water soluble 1 and 2 with ideal lipophilicity (4.91 and 5.03 respectively) values. The additional coordination of a Pd atom to the nitrogen atom of a pyridine ring, the sulfur atom of a tetrahydrothiophene moiety and two chlorine atoms in 1a could be contributing to the observed differences when compared to the monometallic complexes. This report presents impedance technology as a means of correlating drug-likeness of lipophilic phosphine complexes containing similar backbone structures and could prove valuable in filtering drug-like compounds in a drug discovery project.
无标记阻抗技术能够监测细胞在药物或其他化学物质处理后的反应模式。利用该技术,观察到金属配合物的亲脂性与细胞毒性程度之间的相关性。合成了Au(L1)Cl (1)、AuPd(L1)(SC4H8)Cl3 (1a) 和Au(L2)Cl (2) [L1 = 二苯基膦基-2-吡啶;L2 = 2-(2-(二苯基膦基)乙基)-吡啶],并使用阻抗技术监测了其计算机辅助药物相似性和构效关系。在终点测定中,观察到金属配合物的细胞毒性呈剂量依赖性变化,1、1a和2的IC50分别为12.5±2.5、18.3±8.3和16.9±0.5 µM。当使用实时阻抗测定时,观察到与单金属配合物(1和2)相比,双金属配合物(1a)的剂量依赖性反应呈现出表明摄取较慢(在毒性为20 µM时)和细胞恢复较快(在毒性较小的10 µM时)的模式。这些数据与ADMET的研究结果一致,即1a的水溶性较低,亲脂性不理想(AlogP98为6.55),而1和2的水溶性较高,亲脂性理想(分别为4.91和5.03)。与单金属配合物相比,1a中一个钯原子与吡啶环的氮原子、四氢噻吩部分的硫原子和两个氯原子的额外配位可能是导致观察到差异的原因。本报告介绍了阻抗技术,作为一种关联含有相似主链结构的亲脂性膦配合物的药物相似性的方法,在药物发现项目中筛选类药物化合物方面可能具有重要价值。